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Abstract
Visceral leishmaniasis (VL) is a serious parasitic disease causing considerable mortality and major disability in the
Indian subcontinent. It is most neglected tropical disease, particularly in terms of new drug development for the
lack of financial returns. An elimination campaign has been running in India since 2005 that aim to reduce the
incidence of VL to below 1 per 10,000 people at sub-district level. One of the major components in this endeavor is
reducing transmission through early case detection followed by complete treatment. Substantial progress has been
made during the recent years in the area of VL treatment, and the VL elimination initiatives have already saved
many lives by deploying them effectively in the endemic areas. However, many challenges remain to be overcome
including availability of drugs, cost of treatment (drugs and hospitalization), efficacy, adverse effects, and growing
parasite resistance. Therefore, better emphasis on implementation research is urgently needed to determine how
best to deliver existing interventions with available anti-leishmanial drugs. It is essential that the new treatment
options become truly accessible, not simply available in endemic areas so that they may promote healing and save
lives. In this review, we highlight the recent advancement and challenges in current treatment options for VL in
disease endemic area, and discuss the possible strategies to improve the therapeutic outcome.
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Introduction
More than 1 billion people are affected by one or more
neglected infectious diseases worldwide [1, 2], for which we
lack effective, affordable, and easy to use drugs as well as
other control methods. Visceral leishmaniasis (VL), also
known as kala-azar, is one of the disorders in this group
caused by a protozoan parasite, L. donovani and/or L.
infantum, which is transmitted by the bite of an infected
sand fly, Phlebotomus argentipes in the Indian subcontinent
(ISC) [3]. VL results in prolonged fever, anemia, spleno-
megaly, wasting; and is fatal when left untreated [4]. There
are approximately 200–400 thousands new cases every year
occurring predominantly in just six countries: India,
Bangladesh, Sudan, South Sudan, Ethiopia and Brazil [5].
More specifically, >10,000 cases occur in India alone every
year and the state of Bihar accounts for majority of these
cases. These figures, however, do not reflect the true social
impact of this disease because VL has a focal distribution
which is devastating to the affected communities. The cost
of treatment is important when patients need to pay for
treatment as ~75 % of the VL cases in Bihar live below the
poverty threshold of less than US $ 1.0 a day, and this is
similar in other endemic countries although exact data are
scarce [6]. Poverty seriously affects the prognosis of VL be-
cause most of the patients and their families have to pay for
diagnosis, drugs and hospital care, and this is often half or
more of the annual household income [7]. As a result, fam-
ilies with a VL infected member descend deeper into
poverty.
VL has never been featured as high priority for drug
development programs funded by the pharmaceutical in-
dustries because it disproportionately affects the poor
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people in developing countries and are unlikely to yield
good returns on R&D costs. In 2005, the governments of
India, Bangladesh and Nepal signed a joint memoran-
dum of understanding to eliminate VL with the aim to
reduce the incidence to less than 1 per 10,000 people at
sub-district level by the year 2015 [8] which has recently
been extended to the year 2017 [9]. Because of the
anthroponotic nature of the transmission of L.donovani
in the ISC, the use of quality drugs is not only a thera-
peutic tool, but also a tool for VL control. Indeed, hu-
man beings are the only known reservoir of L.donovani,
therefore, identification and proper treatment of parasite
carriers will reduce the parasite biomass and prevents
onward transmission and deaths (Fig. 1). These factors
urge for search of new, effective, less toxic and simplified
treatments to replace or complement the few currently
available drugs. Unfortunately, no new antileishmanial
drugs are expected in near future, because very few
drugs are in the R&D pipeline at various stages of devel-
opment [10]. Furthermore, resistance to first line treat-
ment has long plagued effective treatment of VL in
India, making second line treatments and extended
hospitalization more common. In India, about 5–10 % of
patients with VL, after recovery of acute illness, may de-
velop a chronic cutaneous form called Post kala-azar
dermal leishmaniasis (PKDL) that requires prolonged
and expensive treatment [11]. The emergence of HIV
and its association with VL results in a deadly synergy. A
significant number of patients in Bihar are living with
HIV-VL co-infection [12], and we expect to see more
HIV-VL co-infections in near future which will further
generate major therapeutic challenges [13]. In the fol-
lowing sections, we have briefly reviewed the current
treatment of VL in endemic areas of Bihar, India, and
discuss the challenges and its possible solutions.
Treatment options for VL
There is no vaccine available for VL; hence control of VL
exclusively depends on chemotherapy. Available treatment
options for VL are limited and not up to satisfactory stan-
dards due to problem relating to efficacy, adverse effects,
increasing drug resistance, high cost and need for
hospitalization to complete the full dose of treatment. So
far, many clinical trials have been done in India to optimize
the therapeutic regimens and to protect the efficacy of lim-
ited number of available anti-leishmanials (Tables 1 and 2).
A full list of completed, ongoing and proposed clinical trials
for leishmaniasis in various parts of the world is available
on clinical trial registry site (https://clinicaltrials.gov). In-
deed, important recent advances have been made in the
area of VL treatment that if implemented effectively could
eliminate this disease from most endemic parts of the
world. Table 3 lists the rank wise recommended dose of
anti-leishmanial drugs for VL treatment.
Pentavalent Antimonials
Past experiences have confirmed that response to a drug
varies from region to region. For example, in hyper-
endemic regions of India and adjoining areas of Nepal,
pentavalent antimonials (Sbv also known as sodium stibo-
gluconate) has lost its efficacy with the result that about
two thirds of patients in some of these areas are refractory
to Sbv treatment [14]. However, in Bangladesh, the situ-
ation is different as no resistance to Sbv has been officially
reported. SbVwas recommended and used in Bangladesh
till 2009 as a first line drug [15]. Moreover, Sbv are still the
Fig. 1 Schematic of intervention model based on VL chemotherapy
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Table 1 Currently available anti-leishmanial drugs for treatment of VL: product name, cure rate, mode of action on parasite, advantages and limitations
S.N. Drugs Marketing authotization
and commercial
product













Act as prodrug, inhibit trypanothione
reductase, increase the ROS
Low cost and easy available Parasite resistance especially in India,
cardiotoxic, 30 day iv/im treatment in
hospital, painful injections




Life care, India >98 % in all
regions
Form complexes with sterols mainly
ergosterols of parasite membrane
leading to increase permeability
resulting in cell death
High efficacy, 1st line treatment
in case of antimonial resistance
Dose-limiting renal toxicity, 15–30 day slow






Gilead (AmBisome); >98 % Targeted delivery of drug to infected
macrophages and kill the parasites as
AmB
Highest therapeutic index of
available VL drugs, No need of
hospitalization, substantially less
nephro-toxic than AmB













4 Miltefosine Paladin Labs (Impavido) 94–97 % Modulate cell surface receptors and
inositol metabolism of parasites, and cell
death is mediated by apoptosis, Inhibit
the cytochrome C oxidase
Oral drug, Safe in HIV-VL
co-infection
Teratogenic in experimental animals, originally
developed as an anti- cancer drug, expensive, GI
toxicity, hepato- & renaltoxicity in phase-4
5 Paromomycin Gland Pharma/iOWH 94 % (India) Binds to 30S ribosomal subunit and
interfere with protein biosynthesis,
decrease the membrane potential of
parasite
Cheapest drug An aminoglycoside, therefore nephro- and ototoxicity
possible, but have not been reported in VL patients,
although reversible high tone audiometric shift may
occasionally occur during treatment
6 Pentamidine Sanofi Aventis
(Pentacarinat)
70–80 % Inhibit mitochondrial topoisomerase II
and inhibit the transcription process
Effective in combination
therapy














Table 2 Summary of studies and clinical trials on monotherapy in treatment of visceral leishmaniasis in India
Authors Year Drug Type of study Patients
(N)
Treatment Scheme Cure rate Reference
Thakur et al. 1988 Pentavalent
antimonials
Randomized dose
finding trial of SSG
371 20 vs. 10 mg Sbv+/kg/day for
28 days (i.m)
60–100 % [108]
Thakur et al. 1991 Pentavalent
antimonials
Randomized trial 312 20 mg Sbv+/kg/day for 20,
30 & 40 days (i.m)
71–94 % [109]




15 0.5 mg/kg/day for 28 days (i.v) 93 % [110]








120 AB: 0.5 mg/kg/on alternate day
for 14 days (i.v)
77–98 % [111]
Pentamidinine: 4 mg/kg on alternate days
for 20 injections (i.m)





300 1.0 mg/kg on alternate day,
total dose 20 mg/kg (i.v)
99 % [19]







150 AB: 1.0 mg/kg on alternate day,
total dose 20 mg/kg (i.v)
80–100 % [112]
SSG: 20 vs. 10 mg Sbv+/kg/day
for 30 days (i.m)







80 AB: 0.5 mg/kg on alternate day
for 14 days (i.v)
62–100 % [113]
SSG: 20 mg Sbv+/kg/day
for 40 days (i.m)




80 1.0 mg/kg on daily vs. alternate day,
total dose 20 mg/kg (i.v)
100 % [114]
Thakur et. al. 1994 Amphotericin B
deoxycholate
Dose finding study 120 1.0 mg/kg/day on incremental increasing dose
vs. contantdoase, total dose 20 mg/kg (i.v)
100 % [115]






25 0.75 mg/kg on alternate days (i.v)
total 15 infusions
100 % [116]





100 0.75 mg/kg on alternate days (i.v)
total 15 infusions
100 % [117]





34 1.0 mg/kg/day on alternate days (i.v)
total 10–15 infusions
[18]




288 1.0 mg vs. 0.75 mg vs. 0.5 mg/kg/day
for 20 days (i.v)
79–99 % [118]




130 1.0 mg/kg/day for 20 days (i.v) vs. escalating
dose for 5 days then 1.0 mg/kg/day for 43 days
99 % [119]



















60 AB: 1.0 mg/kg/day for 20 days (i.v) 46.6 and
100 %
[121]
SSG: 20 vs. 10 mg Sbv+/kg/day
for 28 days (i.m)




605 1.0 mg/kg/day for 15 days daily vs.
alternate days (i.v)
100 % [122]






30 2 mg/kg/day on day 1, 2, 3, 4, 5, 6 and 10
vs. days 1, 2, 3, 4 and 10
100 % [123]
Thakur et.al. 2001 Liposomal
Amphotericin B vs.
Randomized trial 34 LAB: 15 mg/kg single dose (i.v) 100 % [28]
AB: 1.0 mg/kg/day for 20 days (i.v)
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Table 2 Summary of studies and clinical trials on monotherapy in treatment of visceral leishmaniasis in India (Continued)
Amphotericin B
deoxycholate


















1.5 mg/kg/days for 5 days (i.v)
Vs
3.0 mg/kg/days for 5 days (i.v)




203 5.0 mg/kg/days for 5 days (i.v) 90 % [29]






153 AB: 1.0 mg/kg/day for 15 dose on alternate
days (i.v); LAB: 2.0 mg/kg/day for 5 days (i.v) Vs.









251 5.0 mg/kg/day (i.v) on 0,1,4, and 9 98.8 % [126]








412 LAB: 10.0 mg/kg/day (i.v) single dose 95.7 and
96.3 %
[27]
AB: 1.0 mg/kg/day for 15 alternate dose (i.v)




86 4 mg/kg/(i.m) for 15 dose
(total dose 60 mg/kg)
93.4 % [127]
Thakur et.al. 1991 Pentamidine Randomized
controlled
comparative study




Group2: 4 mg/kg (i.v) 3 times weekly + SSG 20
mgSbv+/kg (i.m) daily for 20 days
Group3: 4 mg/kg (i.v) 3 times weekly until
spleen were free from parasite + SSG 20 mgSbv
+/kg (i.m) daily for 20 days
Mishra et.al. 1992 Pentamidine Randomized
controlled
comparative study





AB: 0.5 mg.kg (i.v) on alternate days
Das et.al. 2001 Pentamidine Randomized
controlled
comparative study
158 Group1 : 2 mg/kg/day (i.m) on alternate days +





Group 2 : 4 mg/kg/day (i.m) on alternate days
for 30 days
Das et.al. 2009 Pentamidine Randomized
controlled
comparative study





Group 2: Pentamidine- 4 mg/kg/day alternate
days (i.m)
Jha et.al. 1998 Paromomycin Randomized
controlled
comparative study




Group 2: 16 mg/kg/day for 21 days (i.m)
Group 3: 20 mg/kg/day for 21 days (i.m)
Group 4: SSG 20 mg Sbv+/kg/day for 30 days
(i.m)









Group 2 : AB 1 mg/kg/day for 30 days (i.v)
Sunder et.al. 2009 Paromomycin Randomized open
label study
329 Group 1 : 11 mg/kg/day for 14 days (i.m) 82–92.8 % [131]
Group 2 : 11 mg/kg/day for 21 days (i.v)
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first-line drugs in many countries worldwide for all clinical
forms. Major side effects are cardiac arrhythmias, pro-
longed QT interval, ventricular premature beats, ventricu-
lar tachycardia and ventricular fibrillation [16]. There are
accumulating evidence suggesting that Sbv has a dual
mode of action, and acts on both the parasite and the in-
fected macrophage. Upon contact with infected macro-
phages, Sbv stimulates the macrophages to kill the
intracellular parasites and when reaching the parasite, Sbv
is reduced to SbIII, which can directly kill the parasite in-
side phagolysosome by inhibiting trypanothoine reductase
(an enzyme that recycle oxidized trypanothione to keep
the trypanothione in reducing state) [17]. Pentamidine, a
diamidine compound, was the first drug to be used in Sbv
refractory patients, and cured most patients initially, but
after a decade its efficacy also declined from ~100 to 70 %
in hyper-endemic areas of India.
Amphotericin B Dexoycholate (AmB)
Amphotericin B (AmB) was initially recommended in India
for treatment of patient’s refractory to Sbv [18, 19]. How-
ever, due to increasing unresponsiveness of Sbv in endemic
areas, it is currently being used as first line drug for VL
treatment. AmB formulated with sodium deoxycholate was
the first parenteral amphotericin B preparation available
commercially as Fungizone (Bristol-Meyer-Squibb). Several
clinical trials have been conducted till date for treatment of
VL involving AmB (reviewed in ref.[20, 21]) with excellent
cure rate (~100 %) at dose of 0.75–1.0 mg/kg for 15–20
intravenous infusions [22, 23]. The drug has high safety and
efficacy; however, prolonged hospitalization, adverse reac-
tions like high fever with rigor and chills, and the need to
close monitoring of renal functions and electrolyte levels
are well-recognized drawbacks of AmB treatment (Table 2
enlists the studies in India with AmB). The mechanism of
action of AmB is still not fully investigated but it is assumed
that it interferes with the ergosterol in the cell membrane
of Leishmania parasite, causing changes in the membrane
permeability and leakage of intracellular components [24].
Cell death occurs in part because of these permeability
changes, but other mechanisms may also contribute to
AmB antifungal activity. AmB is not active in vitro
against organisms that do not contain sterols in their
cell membranes (e.g., bacteria). Binding to sterols in
mammalian cells (e.g., certain kidney cells, erythro-
cytes) may be responsible for the toxicities associated
with AmB (reviewed in ref. [25]).
Lipid formulations of Amphotericin B (L-AmB)
The advent of Liposome Technology in mid 1960s and
subsequently its application for minimizing dose-limiting
toxicity has added a new paradigm in AmB treatment,
providing a highly effective and safe therapy for many forms
of systemic mycosis. There are six lipid formulations of
Table 2 Summary of studies and clinical trials on monotherapy in treatment of visceral leishmaniasis in India (Continued)
Sinha et.al. 2011 Paromomycin Phase IV open label
study
506 11 mg/kg/day for 21 days (i.m) 94.2 % [132]
Sundar et al. 1998 Miltefosine Phase-I/II safety and
efficacy trial
30 50 mg-250 mg/day for 28 days (oral) 20–100 % [133]
Jha et al. 1999 Miltefosine Phase II randomized
open label, dose
finding
120 50 mg/day for 6 weeks; 50 mg/day for 1 week
followed by 150 mg/day for 3 week; 100 mg/
day for 4 week; 100 mg/day for 1 week
followed by 150 mg/day for 3 week
93–97 % [134]
Sundar et al. 1999 Miltefosine Phase II comparative
clinical trial
45 100-200 mg/day for 28 days 94–100 % [135]
Sundar et al. 2000 Miltefosine Phase II, Comparative
study
54 100 mg/day for 14 days, 21 days or 28 days 88–100 % [136]
Sundar et al. 2002 Miltefosine Randomized open
label comparative
study
398 Miltefosine: 50-100 mg/day for 28 days 97–100 % [58]
AmB:1 mg/kg/day (i.v) for 15 days
Sundar et al. 2003 Miltefosine Open label phase II
dose ranging study
in childrens
39 1.5 or 2.5 mg/kg/day for 28 days 88–90 % [137]
Bhataacharya
et al.
2004 Miletfosine Phase II trial in
childrens
80 2.5 mg/kg/day for 28 days 94 % [138]
Singh et al. 2006 Miltefosine Prospective
multicentric cross
sectional study
125 Miltefosine: 2.5-100 mg/kg/day for 28 days 91.3–
93.2 %
[139]
AmB: 1 mg/kg/day (i.v) for 15 days
Bhattacharya
et al.
2007 Miltefosine Phase IV open label
single arm trial
2109 2.5–100 mg/kg/day for 28 days 93.6–
96.6 %
[140]
Sundar et al. 2012 Miltefosine Open label
comparative study
567 50–100 mg/kg/day for 28 days 90.3 % [61]
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amphotericin B available commercially that differ from
each other with respect to dose, efficacy and toxicities.
These are: i) liposomal amphotericin B (AmBisome®; Gilead
Sciences); ii) Amphotericin B lipid complex (Abelcet®;
ENZON Pharmaceuticals Inc.); iii) AmB cholesteryl
sulfate complex, also called AmB colloidal dispersion
[ABLC] (Amphocil; Sequus Pharmaceuticals); iv)
FUNGISOME™ (Lifecare Innovation Pvt Ltd); v) AmB
emulsion (Amphomul, Bharat Serum and Vaccines,
India); and vi) amphiphilic L-AmB (KALSOME™10,
Life care Innovation, Pvt. Ltd, India). Among these,
Ambisome® is tested in most of the clinical trials and
is probably the most efficacious of all anti-leishmanial
drugs currently available [26]. Most of the clinical tri-
als of L-AmB for the treatment of VL have taken place
in India, where more than 10 different regimens have
been tested (Table 2). Most have been open-label, dose-
finding studies or randomized controlled comparisons. In-
dian experience has demonstrated that L-AmB caused
substantially less toxicity than conventional AmB or
amphotericin B lipid complex (ABLC), but high cost is the
major drawback. Much of research has been focused to re-
duce the course of L-AmB whilst retaining its efficacy, to
limit the cost to patients. Sundar et al. showed that
15 mg/kg of Ambisome® (3 mg/kg on each of 5 injections)
cured 96 % patients [27]. Later on in separate study by
Thakur et al. [28], and Sundar et al. [27, 29, 30] have
demonstrated the efficacy and safety of Ambisome®
achieving efficacy rates in excess of 90 % in single doses of
5–15 mg/kg (Table 2), making it an excellent treatment
option for VL in the ISC. Low toxicity of L-AmB has
made it best treatment option for HIV-VL co-infection pa-
tients. In a study by Sinha et al., excellent long term sur-
vival and retention rate were obtained; however, relapse
within 2 year remained frequent [31]. It can be given safely
in doses as high as 30–40 mg/kg body weight in HIV-
positive VL patients [32, 33]. It has been speculated that
lipid formulations enhance uptake by macrophages (the
site of parasite replication) which results in the
localization of the drug in the macrophage abundant areas
in the body. Ambisome® is currently being used as a first
line drug for the treatment of VL in India, under the kala-
azar elimination program.
Among other lipid formulations, Fungisome™ with the
dose 7.5 mg/kg daily for 2 days showed 100 % cure rate
(without any serious adverse effect) in an open label
randomized study [34, 35]. Abelcet has shown cure rate
90–100 % at total dose of 10–15 mg/kg in SbV resistant
patients [36]. Amphocil was evaluated at three different
doses (7.0, 10 and 15 mg/kg) which showed final cure
rate up to 97 % [37]. Amphomul (single dose: 15 mg/kg
body weight) was found highly effective and safe for
treatment of VL [38]. KALSOMETM is still not tested on
human VL, however, in murine model with 7.5 mg/kg
double dose results in almost complete clearance of par-
asites from both liver and spleen [39].
Paromomycin
Paromomycin is a broad-spectrum aminoglycoside anti-
biotic produced from culture filtrates of Streptomyces
krestomyceticus and with activity against a variety of
Gram-positive and negative organisms, mycobacteria,
protozoa. The anti-leishmanial activity of paromomycin
was first demonstrated in the 1960s [40, 41] and subse-
quently confirmed in vitro and in vivo [42]. This drug was
first tested in Kenya in 1980s for treatment of human VL
[43]. It was registered for treatment of patients with VL in
India in 2006 by Gland Pharma Ltd., Hyderabad, India,
who is now the sole manufacturer for intramuscular paro-
momycin worldwide [44]. Several clinical trials have been
conducted in Kenya, Sudan and India [43, 45–48], and all
these studies have reported that paromomycin, when used
as a single agent or in combination with sodium stiboglu-
conate was highly efficacious and well tolerated in the
treatment of VL. High efficacy rates for paromomycin
(i.m) injection (dose-11 mg/kg for 21 days) has been re-
ported to 98.4 % with initial cure (defined as the initial re-
sponse after complete treatment), and the final cure
(defined as a complete response with no evidence of re-
lapse up to 6 months after an initial cure of 21 days of
treatment) was approximately 94.6 % [49]. Shortening the
Table 3 Recommended treatment regimens for VL in Indian
subcontinent (ranked by preferences)
Anthroponotic VL caused by L.donovani in India, Bangladesh, Bhutan
and Nepal
1. Liposomal amphotericin B: 3–5 mg/kg per daily dose by infusion
given over 3–5-day period up to a total dose of 15 mg/kg (A) by
infusion or 10 mg/kg as a single dose by infusion (A).
2. Combinations (co-administered) (A)
• liposomal amphotericin B (5 mg/kg by infusion, single dose)
plus miltefosine (daily for 7 days, as below)
• liposomal amphotericin B (5 mg/kg by infusion, single dose)
plus paromomycin (daily for 10 days, as below)
• miltefosine plus paromomycin, both daily for 10 days, as below.
3. Amphotericin B deoxycholate: 0.75–1.0 mg/kg per day by infusion,
daily or on alternate days for 15–20 doses (A).
4. Miltefosine: for children aged 2–11 years, 2.5 mg/kg per day; for people
aged ≥12 years and <25 kg body weight, 50 mg/day; 25–50 kg body
weight, 100 mg/day; >50 kg body weight, 150 mg/day; orally for
28 days (A) or Paromomycin: 15 mg (11 mg base) per kg body weight
per day intramuscularly for 21 days (A).
5. Pentavalentantimonials: 20 mg Sb5+/kg per day intramuscularly or
intravenously for 30 days in areas where they remain effective:
Bangladesh, Nepal and the Indian states of Jharkhand, West Bengal
and Uttar Pradesh (A).
Note: Amphotericin-B or Liposomal amphotericin B at higher dose should be
used as rescue treatment in case of non-response
Source: WHO Technical Report Series (2010) Control of the leishmaniasis.
WHO,Geneva [83]
Grade of evidence (A)- evidence based on at least one randomized
controlled trial
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course of this drug from 21 to 14 days has subsequently
shown inferior cure rate [50]. Pain at injection site, ele-
vated liver function tests (LFTs); fever, proteinuria, vomit-
ing, elevations in alkaline phosphatase and bilirubin values
are the main adverse events associated with this drug. The
mechanism of action of paromomycin is thought to be
interference with protein synthesis in the ribosome of the
target organism and inhibit the respiration [51].
Miltefosine
Miltefosine is an alkyl phospholipid compound was the
first effective oral anti-leishmanial agent in VL, and regis-
tered for the treatment of VL in India in 2002, Germany
in 2004, Colombia in 2005 and Bangladesh in 2006
(reviewed in ref. [52]). Miltefosine was originally intended
for breast cancer and other solid tumours [53]. However,
due to dose limiting gastro-intestinal toxicity, it could not
be developed as an oral agent in cancer [54]. Evidence of
excellent anti-leishmanial activity both in-vitro and in ex-
perimental animal models [55–57] prompted the clinical
assessment of oral miltefosine in human VL in1996 [53].
Miltefosine was licensed for use in VL patients in India in
2002 following a Phase III clinical trial in which 94 % long
term cure rate was observed in a dose 50–100 mg/day for
28 days [58]. It was licensed in Europe for treatment of
HIV-VL co-infected patients in 2005 [59, 60]. However,
because of its teratogenic effect in animals and its long-
term residual persistence shown in humans, there is some
concern on unrestricted use of the drug in women of
child-bearing-age. Being orally administrable, miltefosine
has a big advantage of domiciliary treatment. However, it
has the drawback of poor compliance due to its prolonged
treatment regimen well beyond the period in which there
is almost a complete physical recovery of these patients.
Also, with a long half-life of seven days, the chances of
parasites developing resistance are high. A recent studies
showed that after a decade of this drug use in Bihar
(India), 6.8 % of patients relapsed within 6 month of treat-
ment [61]. These considerations suggest for alternative
strategies to protect this drug from failure due to non-
compliance or resistance and to prolong its clinically
useful life. One such way is to combine a short course of
miltefosine, to which compliance should be high, with a
short course of another effective anti-leishmanial com-
pound to obtain complete cure and to protect against
single-agent resistance (Table 2).
Sitamaquine
Sitamaquine is another oral drug after miltefosine devel-
oped by Walter Reed Army Institute of Research (WRAIR,
USA) in collaboration with GlaxoSmithKline (UK). Clinical
trials using this drug have been completed in India, Kenya
and Brazil [62–65] with cure rate ranging from 27 to 87 %.
A major side effect was nephrotoxicity. Exact mechanism
of this drug is not known but it is thought that it targets
succinate dehydrogenate causing oxidative stress in leish-
mania parasites [66]. Further development of this molecule
has been abandoned.
Pentamidine
Pentamidine, an aromatic diamidine that emerged earlier
in Bihar, India as a second line drug to circumvent the
problems of SbV resistant in VL patients. However, due to
inferior cure rate to AmB and toxicity issues (cardiac,
hypotension, diabetes mellitus, gastrointestinal), use of
this drug as monotherapy has been abandoned in endemic
areas [67]. It is commercially available as Pentacarinat®
(Sanofi-Aventis). Pentamidine is currently recommended
as secondary prophylaxis in HIV-VL co-infection. The
mechanism of action of pentamidine in Leishmania and
other kinetoplastids is the inhibition of active transport
system and DNA-mitochondrial complex [68].
Multidrug therapy
In VL, multidrug therapy has been advocated for several
reasons: i) reduce the treatment time and cost; ii) slow
the emergence of parasite resistance as mode of action
of drugs will be different; iii) increase the efficacy rate
even in the case of co-infection [20]. This strategy of
multidrug treatment has been successfully used in the
treatment of tuberculosis, malaria and leprosy. It also
holds promises especially in complicated situations like
HIV co-infection. Ideally, drugs used in combination
therapy must be of synergistic and additive effect. One
of the best approaches is to use one very active drug
with a short half-life with second slow acting drug hav-
ing a longer half-life to clear the remaining parasites. A
comparative overview of different combination therapy
studies for treatment of VL in India has been presented
in Table 4, which suggests that multidrug therapies are
safe and effective.
Immune responses and immunomodulatory
activity of anti-leishmanial drugs
One of the major hurdles for developing an effective vac-
cine for VL, as well as safer and more appropriate drugs
and therapies, has been a limited understanding of the
precise immune mechanisms required for controlling
parasite growth (reviewed in ref. [69]). It has been thought
that clinical efficacy of the disease treatment not only de-
pends on direct effect of drugs alone, but an effective im-
mune response also play critical role in final cure
(Table 1). The use of biological molecules or compounds
to stimulate or modulate innate and cell mediated im-
munity in order to achieve the therapeutic goal has been
tested in both preclinical and clinical studies in treatment
of leishmaniasis (reviewed in ref.[69]). For example, SbV
was not able to clear the parasites in T cell deficient
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BALB/c mice [70] as well as IFNγ and IL-12 gene knock-
out mice [71, 72]. Treatment with exogenous IL-12 along
with SbV resulted in rapid clearance of L.donovani para-
sites (Table 1). Later on in subsequent separate study, it
was reported that treatment with a single-dose anti-IL-10
receptor monoclonal antibody and daily low doses of Sbv
dramatically enhance the therapeutic effects of Sbv in ex-
perimental mice model [73]. These findings strongly sup-
ported the idea that immune mechanisms play an
important role in clinical outcome of disease. This was
further demonstrated by studies on human VL, where
stronger parasitological and clinical cure have been
observed with recombinant human IFNγ along with SSG
compared with the SSG drug alone from India, Brazil and
Kenya [74–76]. Basu et al. reported that SAG induces
generation of reactive oxygen species (ROS) and nitric
oxide (NO) dependent parasite killing via phosphorylation
of ERK1/2 and p38 MAPK [77]. Similar immunomodula-
tory activity is also reported with miltefosine which
induces IFN-γ, TNF-α and IL-12 production from macro-
phages [78]. In PKDL, miltefosine induces significant in-
crease in levels of pro-inflammatory cytokines with
concomitant decrease of anti-inflammatory cytokines via
up-regulation of activation markers CD16 and CD 86 and
Table 4 Studies on combination therapy for VL in India
Authors Year Drug Type of study Patients
(N)










312 Group-1 : Pentamidine (i.v) 4 mg/kg/day three times
weekly until parasitological cure was achieved
Group 1:78 %
Group 2: 84 %
Group 3: 98 %
[128]
Group-2: Pentamidine (i.v) 4 mg/kg/day three times
weekly + SSG (i.m) 20 mg/kg/day for 20 days
Group-3: Pentamidine (i.v) 4 mg/kg/day three times
weekly until parasitological cure was achieved + SSG







22 Paramomycin (i.v) 12 mg/kg/day + 81.8 % [47]







149 Group 1: Paramomycin 12 mg/kg/day + SSG (i.m)
20 mg/kg/day for 21 days
Group 1:92.3 %
Group 2: 93.8 %,
Group 3: 53.1 %
[141]
Group 2: Paramomycin 18 mg/kg/day + SSG (i.m)
20 mg/kg/day for 20 days









158 Group 1: Pentamidine (i.m) 2 mg/kg/day on
alternate days + allopurinol (oral) 15 mg/kg/day for
30 days
Group 1: 91.2 %,
Group 2: 74.3 %
[67]
Group 2: : Pentamidine (i.m) 2 mg/kg/day on








226 Group1: L-AmB (i.v) 5 mg/kg single dose Group 1: 91 %
(78–97);
[142]
Group 2: L-AmB (i.v) 5 mg/kg single dose +
miltefosine 100 mg/day for 10 days
Group 2: 98 %
(87–100);
Group3: L- AmB (i.v) 5 mg/kg single dose +
miltefosine 100 mg/day for 14 days
Group 3: 96 %
(84–99);
Group 4: L-AmB (i.v) 3.75 mg/kg single dose +
miltefosine 100 mg/day for 14 days
Group 4: 96 %
(84–99);
Group 5: L-AmB (i.v) 5 mg/kg single dose +
miltefosine 100 mg/day for 7 days








135 L-AmB (i.v) 5 mg/kg for single dose +miltefosine










634 Group 1: AmB (i.v) 1 mg/kg on alternate days for
30 days
Group 1: 93 %
(88–96);
[144]
Group 2: L-AmB (i.v) 5 mg/kg for single dose +
miltefosine (oral) 50 mg/kg for 7 days
Group 2: 98 %
(93–99)
Group 3: Paramomycin (i.m) 11 mg/kg/day for
10 days
Group 3: 98 %
(93–99);
Group 4: Miltefosine (oral) 50 mg/day for 10 days +
paramomycin (i.m) 11 mg/kg/day for 10 days
Group 4: 99 %
(95–100);
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down regulation of CD14 in circulating monocytes [79].
AmB has been shown to induce the production of TNF-α
[80], IL-6 [81, 82], IL1ß [83–85] and M-CSF [86] from
macrophage and monocytes and simultaneous suppres-
sion of mRNA expression of IL-10 and TNF-ß [87].
Therefore, immune based therapies in combination with
chemotherapy that enhance immune responses to fight
VL are of significant clinical interest. Such novel ap-
proaches may be of very useful for therapies to stimulate
the immune system where patients are immune-
compromised, such as those with HIV-VL co-infection.
Treatment failure and parasite drug resistance
Treatment of VL cases is complicated by patients’ late
presentation at an advanced stage of their illness; and
treatment outcome mainly depends on the interaction be-
tween the drug, the parasite and the human host [88].
Treatment failure is well documented for Sbv but the
mechanism is far from being completely understood. Most
alarming reports came from Bihar (India), where 65 % of
VL-patients were found to be unresponsive to Sbv treat-
ment, while in Nepal, recent reports indicate an unrespon-
siveness rate of up to 24 % in one district [89, 90]. Recently,
it was reported that multiple Sbv resistance mechanism are
circulating in the Indian subcontinent [91] including the
loss of metal reduction, over-expression of thiol metabolism
enzymes, multi drug resistant transporter and reduced drug
uptake due to decreased expression of aquaporins in differ-
ent experimental models [92]. However, knowledge gained
from transcriptional profiling studies and proteomic ap-
proaches emphasized the involvement of HSP’s, histones,
calpain-related proteins and MAPK [93]. While the meta-
bolomics studies have identified many changes and vari-
ation in the lipid composition that alters the membrane
fluidity [94] and amino acid composition [95]. These facts
suggested for the adaptability of the parasite, and therefore,
genome plasticity in Leishmania which has further been
validated by Downing and colleagues, to prove the exist-
ence of different genetic background in drug resistant para-
sites within a single geographical area [96] thereby
consolidating the idea for the existence of drug resistant
phenotypes in the population. Many other reports for the
drug resistance have been available attributing to the role of
efflux transporters, aquaporins, and alterations in the intra-
cellular thiol levels in drug resistant clinical isolates has
been discussed ahead.
AmB resistance, though rare, has been known to result
in changes in the sterol profile where the ergosterol is re-
placed by its precursor cholesta-5,7,24-trien-3-ol in the
membrane of parasite thereby reducing its affinity towards
the drug. Amplification in the extra chromosomal DNA
which has been directly associated with the resistant phe-
notypes [97]. The mechanism of resistance has further
been explored by the proteomic analysis that shed light on
the involvement of energetic pathways which are up-
regulated including the glycolytic and TCA cycle while
documenting the role of reactive oxygen species (ROS)
scavenging pathways and heat shock proteins as additional
weapon for protection against the drug induced stress
[98]. As mentioned above, the role for the efflux pump
(MDR) remains to be the important factor driving the
drug resistance together with the thiol machinery for bet-
ter coping up the ROS induced oxidative stress [99].
Emerging resistance against miltefosine is a matter of
serious concern as it is the only available oral anti-
leishmanial drug. Incomplete treatment and long half-life
of this drug in the circulation has been thought to be one
of the factors for driving the parasite machinery for adapt-
ability against the drug induced stress. The exact mechan-
ism of which could be imputed to the allele specific
mutations in P-glycoprotein-LdRos3 and LdMT [100]
which are responsible for drug uptake in ideal conditions,
but the mutation causes the gene inactivation and conse-
quently decreasing the drug accumulation and drug trans-
location in parasite. Apart from above mentioned reasons
increased drug efflux has been another threatening cause
of drug resistance. Mode of parasite killing involves the in-
duction of apoptosis by accumulation of ROS but the re-
sistant phenotype has been known to alter the cellular
machinery and thereby reducing ROS mediated apoptotic
phenomenon. The resistant phenotypes have also been
known to be armed for coping up the oxidative stress by
up-regulating several important enzymes as superoxide
dismutase and ascorbate peroxidase [101].
Paromomycin, another drug targeting the parasite
mitochondrial protein synthesis machinery has led the
parasite to emerge as a strong survivor with reduced
drug binding to the surface, increased translational activ-
ities with up-regulation of glycolytic enzymes and intra-
cellular proteins, high expression levels of ATP-Binding
Cassette (ABC) transporters [51]. The developments in
the field of omics technologies like DNA microarray,
MALDI, SILAC has further provided newer insight into
the underlying mechanisms for the changes in gene copy
number either by gene deletion, amplification or gene
rearrangements.
Emergence and spreading of drug resistance can dra-
matically jeopardize the VL control program relying on
chemotherapy, as shown in malaria. It is thought that in-
adequate treatment, either regimen or treatment duration,
is the main cause for failure of treatment and resulting in
emergence of drug resistance [102]. Nothing is known
about the dynamics of drug resistant Leishmania popula-
tions in the presence or absence of drug pressure. There-
fore, monitoring of drug efficacy and early reporting are
essential to bring corrective actions in drug policy. This
requires tools, a standardized way to use them and a
structure to implement them: in the mid-term, a network
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of sentinel sites could be established by the VL elimination
program, like it was done in East Africa for malaria [103].
What are the possible solutions?
Although considerable scientific progress has been made
over the past decade in the broad domain of leishmaniasis,
including the genome sequencing of various pathogens
causing different form of leishmaniasis, these have not
had any impact so far on the quality of clinical care for VL
in the field due to very limited number of available anti-
leishmanial drugs. It is very important to safeguard the ef-
fectiveness of these drugs in order to cure patients and to
sustain the VL control. For this, the uninterrupted supply
of quality drugs, the promotion of treatment adherence
and the monitoring of treatment effectiveness as well as
drug resistance will be pivotal. One of the major hurdles
for identifying VL patients who are unlikely to respond
adequately to chemotherapy, has been a limited under-
standing of the precise immune mechanisms required for
controlling parasite growth, particularly the immune
mechanisms that are generated following drug treatment.
Anti-leishmanial drugs as monotherapy are high risk of
emergence of resistant parasites [16], therefore multidrug
therapy needs to be recommended. Another important
problem is disease relapse following drug treatment, and
at present there are no good prognostic markers to iden-
tify individuals that might fail drug treatment. Because the
knowledge on mechanisms of emergence of drug resist-
ance, its dynamics and the impact of the introduction of
new drugs is poor, and validated methods to monitor
treatment of effectiveness under routine conditions do not
exist, it is therefore very urgent to develop new tools to
allow monitoring treatment effectiveness and drug resist-
ance in order to support the drug policy of the VL elimin-
ation program. Furthermore, treatment outcome (the end
of treatment) is not definite and patients need to be
followed up 6 months after treatment to assess cure. This
makes monitoring treatment effectiveness in routine con-
ditions difficult, as patients may not come back for the re-
quested visit 6 months post-treatment. Hence there is a
need to compare existing and develop new approaches to
monitor treatment effectiveness at the program level. Sev-
eral possibilities exist: to work with proxy indicators, to
develop a method adapted from the retrospective cohort
analysis used in TB programs, to give incentives as trans-
port allowances to patients etc.
Importantly, patients with PKDL represent an important
but largely neglected reservoir of infection that perpetuates
anthroponotic Leishmania donovani disease in India, and
focal VL outbreaks have been linked to an index case of
PKDL [104]. Treatment of PKDL in India is widely
regarded as unsatisfactory, and the low incidence of PKDL
in India makes any prospective clinical study challenging.
Lack of animal models for PKDL is another challenge for
laboratory testing of new drugs. Therefore, more research
on an intervention that can reduce the risk of developing
PKDL; and characterization of parasite strain are needed to
resolve the mystery of this disease.
The use of chemotherapy alone as control tool is limited
by the fact that only sick people will be treated. There are
asymptomatic carriers of the parasite (estimated 6 times
more than VL patients) [105–107], and in the absence of
chemoprophylaxis of leishmaniasis, these will obviously not
be exposed to the drug [3]. Exact role of asymptomatic in-
fection in disease transmission is unknown, but control
programs should take them into consideration, hence role
of asymptomatic should be quickly elucidated in context to
VL transmission.
Last but not the least, not only VL treatment programs
should be maintained and improved, but research should
also be taken into consideration those parasite reservoirs
in populations in order to reduce the risk of transmission.
Programs based on management of vector control should
be continued as a critical part of treatment strategy. Re-
search on development of safe and effective vaccine have
to be promoted that could make a significant impact on
the re-emergence of VL cases and sustain the transmission
level in endemic areas.
Conclusion
In the absence of effective vaccine and vector control mea-
sures, control of VL and PKDL almost exclusively depends
on chemotherapy. The available drugs are costly and may
require hospitalization that needs monitoring which cause
substantial loss of income for affected families. Emergence
of drug resistance further complicates the treatment of dis-
ease. Multidrug regimens for VL hold much promise and,
experiences with single dose L-AmB are excellent and this
will have obvious benefits to the patients who will not re-
quire hospital care and loss of wages. However, more stud-
ies are required on treatment of PKDL and HIV-VL co-
infections as they serve as silent reservoir in endemic areas,
and as such will jeopardize the sustainability of VL elimin-
ation in the ISC. We have now entered in the VL elimin-
ation year, and it is best time to repeat the experience of
smallpox and polio eradication in order to open a whole
new public health era for next generations.
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